
Danish pharmaceutical company Bavarian Nordic is entering into a marketing and distribution agreement with Dynavac for the launch of a new hepatitis B vaccine in Germany, according to a press release published on Thursday.
Bavarian Nordic will market and distribute the Heplisav B vaccine for Dynavax. The companies expect it to be launched in the fourth quarter of 2021.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app